Neuromed at ANLLF 2025 Amiens: The French EEG solution

A congress dedicated to epileptology, an opportunity for diagnostic innovations

From September 26 to 28, 2025, the Association des Neurologues Libéraux de Langue Française (ANLLF) will be holding its annual congress in Amiens, a unifying event for neurologists, epileptologists and healthcare professionals specializing in the management of epilepsy. In France, this pathology affects some 600,000 people (source: Haute Autorité de Santé, 2021), with a major challenge: reducing diagnostic delays, since almost 30% of epilepsy patients do not benefit from an EEG assessment within six months of the onset of symptoms(INSERM study, 2022).

In this context, Neuromeda French company specializing in EEG technologies, will be presenting its new range of electroencephalographs developed and manufactured in the Vaucluse region (84). Already tested in hospitals – notably the Hôpital Européen de Marseille and CHU Cochin (Paris) – these devices feature three key advantages:

Simplified connection (plug-and-play, no complex calibration).
Optimized signal quality (reduced artifacts for more reliable interpretation).
No software licenses, limiting recurring costs for establishments.

An approach that meets the concrete needs of neurology departments, where speed, precision and budget control are priorities.

Clinically validated performance

Neuromed devices have been evaluated under real-life conditions in several hospitals, including the Hôpital Européen de Marseille. Feedback from the medical teams highlights :

A 40% reduction in exam preparation time, thanks to an intuitive interface.
Improved detection of epileptiform activity, with sensitivity comparable to high-end systems on the market(Neuromed internal data, 2023).
Simplified maintenance, with responsive after-sales service (response time within 48 hours, compared with 7 to 10 days for some international competitors).

Unlike other manufacturers, whose solutions often require costly annual licenses (up to €10,000/year), Neuromed offers a transparent business model, with no hidden costs. A decisive advantage for public hospitals and private clinics, faced with increasing budget constraints.

Made in France, a strategic asset for healthcare establishments

Over and above technical performance, the choice of 100% French production (manufacturing site in Vaucluse) offers concrete advantages:

Short delivery times (2 to 4 weeks, compared with several months for imports).
Full compliance with European standards (CE class IIa certification).
Local support, with a technical team available for rapid training and troubleshooting.

This commitment is in line with the government’s drive for medical sovereignty, particularly in the wake of the health crisis(Plan France 2030, health section).